Ricardo Azziz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4271094/publications.pdf

Version: 2024-02-01

406 papers	36,514 citations	4955 84 h-index	3647 180 g-index
430 all docs	430 docs citations	430 times ranked	15404 citing authors

#	Article	IF	Citations
1	The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2745-2749.	1.8	2,190
2	Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4237-4245.	1.8	1,811
3	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility, 2009, 91, 456-488.	0.5	1,639
4	Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3078-3082.	1.8	1,372
5	Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4133-4160.	1.8	1,117
6	Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology, 2011, 7, 219-231.	4.3	1,062
7	Utility, Limitations, and Pitfalls in Measuring Testosterone: An Endocrine Society Position Statement. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 405-413.	1.8	1,048
8	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndromeâ€â€¡. Human Reproduction, 2018, 33, 1602-1618.	0.4	1,015
9	Polycystic ovary syndrome. Nature Reviews Disease Primers, 2016, 2, 16057.	18.1	1,004
10	Androgen Excess in Women: Experience with Over 1000 Consecutive Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 453-462.	1.8	959
11	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 2018, 110, 364-379.	0.5	759
12	Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility, 2016, 106, 6-15.	0.5	741
13	Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 48-53.	1.8	606
14	Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3078-3082.	1.8	552
15	Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction, 2008, 23, 462-477.	0.4	499
16	Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertility and Sterility, 2005, 83, 1454-1460.	0.5	470
17	Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovary Syndrome: A Multicenter, Double Blind, Placebo-Controlled Trial¹. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1626-1632.	1.8	457
18	Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8573-8578.	3.3	437

#	Article	IF	Citations
19	Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4650-4658.	1.8	398
20	Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovary Syndrome: A Multicenter, Double Blind, Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1626-1632.	1.8	378
21	Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 781-785.	1.8	357
22	Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertility and Sterility, 2002, 77, 1095-1105.	0.5	352
23	Impact of Obesity on the Risk for Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 162-168.	1.8	319
24	Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertility and Sterility, 2001, 75, 53-58.	0.5	315
25	Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nature Communications, 2015, 6, 7502.	5.8	314
26	Polycystic Ovary Syndrome. Obstetrics and Gynecology, 2018, 132, 321-336.	1.2	314
27	Visually scoring hirsutism. Human Reproduction Update, 2010, 16, 51-64.	5.2	272
28	Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertility and Sterility, 2005, 83, 1717-1723.	0.5	236
29	miRNA-93 Inhibits GLUT4 and Is Overexpressed in Adipose Tissue of Polycystic Ovary Syndrome Patients and Women With Insulin Resistance. Diabetes, 2013, 62, 2278-2286.	0.3	231
30	Clinical review 56: Nonclassic adrenal hyperplasia: current concepts.. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 810-815.	1.8	222
31	Screening for 21-hydroxylaseâ€“deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertility and Sterility, 1999, 72, 915-925.	0.5	215
32	Development of a Health-Related Quality-of-Life Questionnaire (PCOSQ) for Women with Polycystic Ovary Syndrome (PCOS)1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1976-1987.	1.8	211
33	Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2005, 62, 644-649.	1.2	205
34	Idiopathic Hirsutism*. Endocrine Reviews, 2000, 21, 347-362.	8.9	195
35	Degree of Facial and Body Terminal Hair Growth in Unselected Black and White Women: Toward a Populational Definition of Hirsutism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1345-1350.	1.8	186
36	Effects of Race and Family History of Type 2 Diabetes on Metabolic Status of Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 66-71.	1.8	182

#	Article	IF	Citations
37	Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 810-815.	1.8	171
38	Replication of association ofDENND1AandTHADAvariants with polycystic ovary syndrome in European cohorts. Journal of Medical Genetics, 2012, 49, 90-95.	1.5	165
39	21-Hydroxylaseâ€“deficient nonclassic adrenal hyperplasia is a progressive disorder: A multicenter study. American Journal of Obstetrics and Gynecology, 2000, 183, 1468-1474.	0.7	163
40	21-Hydroxylase Deficiency in Female Hyperandrogenism: Screening and Diagnosis. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 577-584.	1.8	157
41	The evaluation and management of hirsutism*1. Obstetrics and Gynecology, 2003, 101, 995-1007.	1.2	157
42	Development of a Health-Related Quality-of-Life Questionnaire (PCOSQ) for Women with Polycystic Ovary Syndrome (PCOS). Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1976-1987.	1.8	155
43	Reproductive Outcome of Women with 21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3451-3456.	1.8	146
44	Referral Bias in Defining the Phenotype and Prevalence of Obesity in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1088-E1096.	1.8	139
45	DHEA, DHEAS and PCOS. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 213-225.	1.2	138
46	CYP11B1 Mutations Causing Non-Classic Adrenal Hyperplasia due to 11Â-Hydroxylase Deficiency. Human Molecular Genetics, 1997, 6, 1829-1834.	1.4	136
47	Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Human Reproduction Update, 2017, 23, 580-599.	5.2	136
48	Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 193-205.	2.2	135
49	Role of diet in the treatment of polycystic ovary syndrome. Fertility and Sterility, 2006, 85, 679-688.	0.5	133
50	Diagnostic criteria for polycystic ovary syndrome: A reappraisal. Fertility and Sterility, 2005, 83, 1343-1346.	0.5	131
51	Use of metformin in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 2008, 199, 596-609.	0.7	130
52	Anti-MÃ¼llerian Hormone in PCOS: A Review Informing International Guidelines. Trends in Endocrinology and Metabolism, 2019, 30, 467-478.	3.1	130
53	Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6072-6076.	1.8	129
54	Epigenetic Mechanism Underlying the Development of Polycystic Ovary Syndrome (PCOS)-Like Phenotypes in Prenatally Androgenized Rhesus Monkeys. PLoS ONE, 2011, 6, e27286.	1.1	128

#	Article	IF	Citations
55	Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. Journal of Clinical Epidemiology, 2004, 57, 1279-1287.	2.4	127
56	Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertility and Sterility, 1998, 69, 286-292.	0.5	123
57	Reproductive endocrinologic alterations in female asymptomatic obesity. Fertility and Sterility, 1989, 52, 703-725.	0.5	119
58	Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. Fertility and Sterility, 2006, 86, 411-417.	0.5	117
59	Polycystic ovary syndrome: an ancient disorder?. Fertility and Sterility, 2011, 95, 1544-1548.	0.5	117
60	Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertility and Sterility, 2010, 93, 1938-1941.	0.5	113
61	Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertility and Sterility, 1998, 70, 274-278.	0.5	112
62	Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertility and Sterility, 2016, 106, 1510-1520.e2.	0.5	112
63	The adrenal and polycystic ovary syndrome. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 331-342.	2.6	109
64	Defining hirsutism in Chinese women: a cross-sectional study. Fertility and Sterility, 2011, 96, 792-796.	0.5	107
65	Adrenal Androgen Excess in the Polycystic Ovary Syndrome: Sensitivity and Responsivity of the Hypothalamic-Pituitary-Adrenal Axis1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2317-2323.	1.8	105
66	Exploring the potential association between brominated diphenyl ethers, polychlorinated biphenyls, organochlorine pesticides, perfluorinated compounds, phthalates, and bisphenol a in polycystic ovary syndrome: a caseâ€“control study. BMC Endocrine Disorders, 2014, 14, 86.	0.9	105
67	Hyperandrogenemia in patients presenting with acne. Fertility and Sterility, 2001, 75, 889-892.	0.5	104
68	Effects of Aging on Adrenal Function in the Human: Responsiveness and Sensitivity of Adrenal Androgens and Cortisol to Adrenocorticotropin in Premenopausal and Postmenopausal Women1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 48-54.	1.8	103
69	DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Healthâ€"National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Womenâ€™s Ischemia Syndrome Evaluation (WISE). Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4985-4992.	1.8	101
70	PCOS: a diagnostic challenge. Reproductive BioMedicine Online, 2004, 8, 644-648.	1.1	100
71	Association of Androgen Receptor CAG Repeat Polymorphism and Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1939-1945.	1.8	100
72	Epigenetics in polycystic ovary syndrome: a pilot study of global DNA methylation. Fertility and Sterility, 2010, 94, 781-783.e1.	0.5	96

#	Article	IF	Citations
73	Adrenal Androgen Excess in the Polycystic Ovary Syndrome: Sensitivity and Responsivity of the Hypothalamic-Pituitary-Adrenal Axis. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2317-2323.	1.8	95
74	The phenotype of hirsute women: a comparison ofÂpolycystic ovary syndrome and 21-hydroxylaseâ€“deficient nonclassic adrenal hyperplasia. Fertility and Sterility, 2010, 94, 684-689.	0.5	94
75	Androgen excess: Investigations and management. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 98-118.	1.4	94
76	Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology. Fertility and Sterility, 1992, 58, 302-306.	0.5	93
77	Androgen excess is the key element in polycystic ovary syndrome. Fertility and Sterility, 2003, 80, 252-254.	0.5	93
78	Congenital Adrenal Hyperplasia. Journal of Pediatric and Adolescent Gynecology, 2011, 24, 116-126.	0.3	93
79	FTO and MC4R Gene Variants Are Associated with Obesity in Polycystic Ovary Syndrome. PLoS ONE, 2011, 6, e16390.	1.1	92
80	Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia, 2012, 55, 2636-2645.	2.9	92
81	Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertility and Sterility, 2005, 84, 766-769.	0.5	90
82	New insights into the genetics of polycystic ovary syndrome. Nature Reviews Endocrinology, 2016, 12, 74-75.	4.3	90
83	Introduction. Fertility and Sterility, 2016, 106, 4-5.	0.5	89
84	Congenital adrenal hyperplasia: long-term results following vaginal reconstruction. Fertility and Sterility, 1986, 46, 1011-1014.	0.5	88
85	Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertility and Sterility, 1999, 71, 671-674.	0.5	86
86	Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertility and Sterility, 2006, 86, S7-S8.	0.5	84
87	Favourable metabolic effects of a eucaloric lowerâ€carbohydrate diet in women with <scp>PCOS</scp>. Clinical Endocrinology, 2013, 79, 550-557.	1.2	84
88	Systems Genetics Reveals the Functional Context of PCOS Loci and Identifies Genetic and Molecular Mechanisms of Disease Heterogeneity. PLoS Genetics, 2015, 11, e1005455.	1.5	84
89	Prospective Association of Polycystic Ovary Syndrome With Coronary Artery Calcification and Carotid-Intima-Media Thickness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2688-2694.	1.1	83
90	11Î²-Hydroxylase deficiency in hyperandrogenism. Fertility and Sterility, 1991, 55, 733-741.	0.5	82

#	Article	IF	Citations
91	A Multicenter Study of Women with Nonclassical Congenital Adrenal Hyperplasia: Relationship between Genotype and Phenotype. Molecular Genetics and Metabolism, 2000, 71, 527-534.	0.5	82
92	Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertility and Sterility, 2003, 79, 932-937.	0.5	82
93	Variants in the 5Î±-Reductase Type 1 and Type 2 Genes Are Associated with Polycystic Ovary Syndrome and the Severity of Hirsutism in Affected Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4085-4091.	1.8	82
94	MicroRNA-223 Expression Is Upregulated in Insulin Resistant Human Adipose Tissue. Journal of Diabetes Research, 2015, 2015, 1-8.	1.0	81
95	Diagnosis of Polycystic Ovary Syndrome. Clinical Obstetrics and Gynecology, 2007, 50, 168-177.	0.6	80
96	Idiopathic Hirsutism. , 2000, 21, 347-362.		80
97	Effects of Aging on Adrenal Function in the Human: Responsiveness and Sensitivity of Adrenal Androgens and Cortisol to Adrenocorticotropin in Premenopausal and Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 48-54.	1.8	80
98	Resistin Stimulation of 17Î±-Hydroxylase Activity in Ovarian Theca Cells in Vitro: Relevance to Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4852-4857.	1.8	78
99	Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. Human Reproduction, 2019, 34, 127-136.	0.4	77
100	Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: A populational study. Gynecological Endocrinology, 1999, 13, 394-400.	0.7	75
101	The Evaluation and Management of Hirsutism. Obstetrics and Gynecology, 2003, 101, 995-1007.	1.2	75
102	Novel Pathway of Adipogenesis through Cross-Talk between Adipose Tissue Macrophages, Adipose Stem Cells and Adipocytes: Evidence of Cell Plasticity. PLoS ONE, 2011, 6, e17834.	1.1	73
103	Adenomyosis: current perspectives. Obstetrics and Gynecology Clinics of North America, 1989, 16, 221-35.	0.7	72
104	Genetics of polycystic ovary syndrome. Expert Review of Molecular Diagnostics, 2017, 17, 723-733.	1.5	71
105	Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. Fertility and Sterility, 2004, 81, 126-131.	0.5	70
106	Pro-453 to Ser mutation in CYP21 is associated with nonclassic steroid 21-hydroxylase deficiency.. Molecular Endocrinology, 1992, 6, 1211-1215.	3.7	69
107	Carriers of 21-Hydroxylase Deficiency Are Not at Increased Risk for Hyperandrogenism*. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 479-485.	1.8	69
108	NonClassic Congenital Adrenal Hyperplasia. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 625105.	1.6	69

#	Article	IF	Citations
109	Socioeconomic and Racial Predictors of Undergoing Laparoscopic Hysterectomy for Selected Benign Diseases: Analysis of 341487 Hysterectomies. Journal of Minimally Invasive Gynecology, 2008, 15, 11-15.	0.3	68
110	The prevalence of androgen excess among patients with minimal unwanted hair growth. American Journal of Obstetrics and Gynecology, 2004, 191, 1914-1920.	0.7	67
111	Abnormal Expression of Genes Involved in Inflammation, Lipid Metabolism, and Wnt Signaling in the Adipose Tissue of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E765-E770.	1.8	67
112	Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2875-2891.	1.8	67
113	Fertility evaluation of infertile women: a committee opinion. Fertility and Sterility, 2021, 116, 1255-1265.	0.5	67
114	Microsurgery alone or with INTERCEED Absorbable Adhesion Barrier for pelvic sidewall adhesion re-formation. The INTERCEED (TC7) Adhesion Barrier Study Group II. Surgery, Gynecology & Obstetrics, 1993, 177, 135-9.	0.6	67
115	Stein and Leventhal: 80 years on. American Journal of Obstetrics and Gynecology, 2016, 214, 247.e1-247.e11.	0.7	66
116	Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 575-585.	1.8	66
117	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. Journal of Women's Health, 2016, 25, 875-881.	1.5	65
118	Genital Anomalies in Childhood. Clinical Obstetrics and Gynecology, 1987, 30, 682-696.	0.6	64
119	Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 3406-3411.	1.8	64
120	The Age-Associated Decline of Androgens in Reproductive Age and Menopausal Black and White Women. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4730-4733.	1.8	64
121	Minimal Response of Circulating Lipids in Women with Polycystic Ovary Syndrome to Improvement in Insulin Sensitivity with Troglitazone. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5137-5144.	1.8	62
122	Adrenal Function during Childhood and Puberty in Daughters of Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3282-3288.	1.8	62
123	Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS. Metabolism: Clinical and Experimental, 2014, 63, 1257-1264.	1.5	62
124	Laparoscopic surgery for ectopic pregnancies: technology assessment and public health implications. Fertility and Sterility, 1993, 59, 487-498.	0.5	61
125	Laser hair reduction in the hirsute patient: a critical assessment. Human Reproduction Update, 2002, 8, 169-181.	5.2	60
126	Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertility and Sterility, 2009, 92, 643-647.	0.5	59

#	Article	IF	Citations
127	Obesity and reproduction: a committee opinion. Fertility and Sterility, 2021, 116, 1266-1285.	0.5	59
128	Acute Adrenocorticotropin-(1â€“24) (ACTH) Adrenal Stimulation in Eumenorrheic Women: Reproducibility and Effect of ACTH Dose, Subject Weight, and Sampling Time*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1273-1279.	1.8	58
129	The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1967-E1971.	1.8	57
130	Further Investigation in Europeans of Susceptibility Variants for Polycystic Ovary Syndrome Discovered in Genome-Wide Association Studies of Chinese Individuals. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E182-E186.	1.8	57
131	Carriers of 21-Hydroxylase Deficiency Are Not at Increased Risk for Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 479-485.	1.8	57
132	Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertility and Sterility, 2009, 91, 1848-1852.	0.5	56
133	Identification and characterization of cytosolic sulfotransferases in normal human endometrium. Chemico-Biological Interactions, 1998, 109, 329-339.	1.7	55
134	Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertility and Sterility, 2011, 95, 1736-1741.e11.	0.5	55
135	Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource. Human Reproduction, 2019, 34, 2254-2265.	0.4	55
136	3Î²-Hydroxysteroid dehydrogenase deficiency in hyperandrogenism. American Journal of Obstetrics and Gynecology, 1993, 168, 889-895.	0.7	54
137	Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria. Fertility and Sterility, 2014, 101, 1135-1141.e2.	0.5	53
138	Laparoscopic evaluation following failure to achieve pregnancy after ovulation induction with clomiphene citrate. Fertility and Sterility, 2003, 80, 1450-1453.	0.5	52
139	Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Therapeutics and Clinical Risk Management, 2008, Volume 4, 487-492.	0.9	52
140	21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia: The Great Pretender. Seminars in Reproductive Medicine, 2003, 21, 295-300.	0.5	51
141	Regulation of Adiponectin Secretion by Adipocytes in the Polycystic Ovary Syndrome: Role of Tumor Necrosis Factor-Î±. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 935-942.	1.8	51
142	Nonclassic Congenital Adrenal Hyperplasia. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 1-11.	1.6	49
143	Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome. Human Reproduction, 2014, 29, 1508-1517.	0.4	49
144	Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1â€“24) stimulation in hyperandrogenic women. American Journal of Obstetrics and Gynecology, 1995, 172, 1251-1256.	0.7	48

#	Article	IF	Citations
145	Polycystic Ovary Syndrome, Insulin Resistance, and Molecular Defects of Insulin Signaling. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4085-4087.	1.8	48
146	Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 3406-3411.	1.8	48
147	Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism?. Fertility and Sterility, 2011, 96, 1266-1270.e1.	0.5	47
148	The Development of the Polycystic Ovary Syndrome: Family History as a Risk Factor. Trends in Endocrinology and Metabolism, 1998, 9, 55-58.	3.1	46
149	The Effects of Prolonged Hypertestosteronemia on Adrenocortical Biosynthesis in Oophorectomized Women*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 1025-1030.	1.8	45
150	Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation.. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 400-405.	1.8	45
151	Heritability and the risk of developing androgen excess. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 261-268.	1.2	45
152	FSH Beyond Fertility. Frontiers in Endocrinology, 2019, 10, 136.	1.5	45
153	On the Origin of the Elevated 17-Hydroxyprogesterone Levels after Adrenal Stimulation in Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 431-436.	1.8	44
154	Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess. Fertility and Sterility, 2005, 83, 371-375.	0.5	44
155	A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause. Menopause, 2012, 19, 54-61.	0.8	43
156	Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded?. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4421-4427.	1.8	43
157	Role of the Ovary in the Adrenal Androgen Excess of Hyperandrogenic Women. Fertility and Sterility, 1998, 69, 851-859.	0.5	42
158	Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. Fertility and Sterility, 2004, 81, 120-125.	0.5	42
159	Promoting Residents' Professional Development and Academic Productivity Using a Structured Faculty Mentoring Program. Teaching and Learning in Medicine, 2010, 22, 93-96.	1.3	42
160	The Expression of the miR-25/93/106b Family of Micro-RNAs in the Adipose Tissue of Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2754-E2761.	1.8	42
161	Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertility and Sterility, 2007, 87, 862-869.	0.5	41
162	Socioeconomic Status and Polycystic Ovary Syndrome. Journal of Women's Health, 2011, 20, 413-419.	1.5	41

#	Article	IF	Citations
163	Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 400-405.	1.8	41
164	Genes for Enzymes Regulating Dehydroepiandrosterone Sulfonation Are Associated with Levels of Dehydroepiandrosterone Sulfate in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2659-2664.	1.8	38
165	Polycystic Ovarian Syndrome: Long-Term Health Consequences. Seminars in Reproductive Medicine, 2017, 35, 271-281.	0.5	38
166	O-16. Fertility and Sterility, 2006, 86, S7-S8.	0.5	37
167	Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocrine Connections, 2019, 8, R71-R75.	0.8	37
168	Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies. Fertility and Sterility, 2001, 76, 730-735.	0.5	36
169	Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertility and Sterility, 2004, 82, 973-975.	0.5	36
170	Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation Initiative. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 1-17.	1.6	35
171	Risks for Gestational Diabetes Mellitus and Pregnancy-Induced Hypertension Are Increased in Polycystic Ovary Syndrome. BioMed Research International, 2013, 2013, 1-6.	0.9	35
172	Polycystic Ovary Syndrome Is Associated with an Increased Prevalence of Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2010, 55, 1085-1089.	1.1	34
173	Association study of four key folliculogenesis genes in polycystic ovary syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 2010, 117, 756-760.	1.1	34
174	Effects of Endogenous Androgens and Abdominal Fat Distribution on the Interrelationship Between Insulin and Non-Insulin-Mediated Glucose Uptake in Females. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1541-1548.	1.8	34
175	Repeated freezing and thawing does not generally alter assay results for several commonly studied reproductive hormones. Fertility and Sterility, 2001, 76, 823-825.	0.5	33
176	Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters. Fertility and Sterility, 2006, 86, 1688-1693.	0.5	33
177	The time has come to simplify the evaluation of the hirsute patient. Fertility and Sterility, 2000, 74, 870-872.	0.5	32
178	Independent Confirmation of Association between Metabolic Phenotypes of Polycystic Ovary Syndrome and Variation in the Type 6 17Î²-Hydroxysteroid Dehydrogenase Gene. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 5034-5038.	1.8	32
179	Berberine inhibits the proliferation ofÂhuman uterine leiomyoma cells. Fertility and Sterility, 2015, 103, 1098-1106.	0.5	32
180	Effect of obesity on the response to acute adrenocorticotropin stimulation in eumenorrheic women. Fertility and Sterility, 1991, 56, 427-433.	0.5	31

#	Article	IF	Citations
181	Molecular abnormalities of the 21-hydroxylase gene in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to short-term adrenal stimulation. American Journal of Obstetrics and Gynecology, 1995, 172, 914-918.	0.7	31
182	Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome. Fertility and Sterility, 2011, 95, 2538-2541.e6.	0.5	31
183	Ovulation After Glucocorticoid Suppression of Adrenal Androgens in the Polycystic Ovary Syndrome Is Not Predicted by the Basal Dehydroepiandrosterone Sulfate Level. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 946-950.	1.8	31
184	Stability of Adrenocortical Steroidogenesis over Time in Healthy Women and Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5558-5562.	1.8	30
185	Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. Fertility and Sterility, 2008, 90, 2291-2297.	0.5	30
186	Association of CYP3A7*1C and Serum Dehydroepiandrosterone Sulfate Levels in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2909-2912.	1.8	30
187	Total Estrogen Time and Obstructive Coronary Disease in Women: Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Women's Health, 2009, 18, 1315-1322.	1.5	30
188	Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage. Molecular Human Reproduction, 2012, 18, 320-324.	1.3	30
189	Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. Journal of reproductive medicine, The, 1999, 44, 870-4.	0.2	30
190	Postoperative recuperation: relation to the extent of endoscopic surgery. Fertility and Sterility, 1989, 51, 1061-1064.	0.5	29
191	The Effect of 17Î²-Estradiol on Adrenocortical Sensitivity, Responsiveness, and Steroidogenesis in Postmenopausal Women1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 519-524.	1.8	29
192	Adrenocortical Secretion of Dehydroepiandrosterone in Healthy Women: Highly Variable Response to Adrenocorticotropin¹. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2513-2517.	1.8	29
193	Ovulation After Glucocorticoid Suppression of Adrenal Androgens in the Polycystic Ovary Syndrome Is Not Predicted by the Basal Dehydroepiandrosterone Sulfate Level1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 946-950.	1.8	28
194	First Evidence of Genetic Association Between AKT2 and Polycystic Ovary Syndrome. Diabetes Care, 2008, 31, 2284-2287.	4.3	28
195	Examination of the chin or lower abdomen only for the prediction of hirsutism. Fertility and Sterility, 2000, 74, 980-983.	0.5	27
196	From the eye of the nurses: 360-degree evaluation of residents. Journal of Continuing Education in the Health Professions, 2009, 29, 105-110.	0.4	27
197	Negative association between androgen receptor gene CAG repeat polymorphism and polycystic ovary syndrome? A systematic review and meta-analysis. Molecular Human Reproduction, 2012, 18, 498-509.	1.3	27
198	Evolutionary determinants of polycystic ovary syndrome: part 2. Fertility and Sterility, 2016, 106, 42-47.	0.5	27

#	Article	IF	Citations
199	Adrenocortical Secretion of Dehydroepiandrosterone in Healthy Women: Highly Variable Response to Adrenocorticotropin. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2513-2517.	1.8	27
200	Advances in the diagnosis and treatment of the hirsute patient. Current Opinion in Obstetrics and Gynecology, 1995, 7, 344-350.	0.9	26
201	The Role Of The Adrenal Cortex In Polycystic Ovary Syndrome. Obstetrics and Gynecology Clinics of North America, 2001, 28, 63-75.	0.7	26
202	Effect of oral estrogen on substrate utilization in postmenopausal women. Fertility and Sterility, 2008, 90, 1275-1278.	0.5	26
203	A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 1-5.	1.6	26
204	The Treatment of Hyperandrogenism with Oral Contraceptives. Seminars in Reproductive Medicine, 1989, 7, 246-254.	0.5	25
205	Adrenocortical hyperresponsivity to adrenocorticotropic hormone: a mechanism favoring the normal production of cortisol in 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertility and Sterility, 2000, 74, 329-334.	0.5	25
206	Altered autophosphorylation of the insulin receptor in the ovary of a woman with polycystic ovary syndrome. Fertility and Sterility, 2001, 75, 625-628.	0.5	25
207	Nonreplication of the Type 5 17Î²-Hydroxysteroid Dehydrogenase Gene Association with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 300-303.	1.8	25
208	The Relationship of Menopausal Status and Rapid Menopausal Transition with Carotid Intima-Media Thickness Progression in Women: A Report from the Los Angeles Atherosclerosis Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4432-4440.	1.8	25
209	Polycystic Ovary Syndrome: What's in a Name?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1142-1145.	1.8	25
210	Berberine regulates the protein expression of multiple tumorigenesis-related genes in hepatocellular carcinoma cell lines. Cancer Cell International, 2017, 17, 59.	1.8	25
211	The pressing need for standardization in epidemiologic studies of PCOS across the globe. Gynecological Endocrinology, 2019, 35, 1-3.	0.7	25
212	The development and use of a standard symphysial-fundal height growth curve in the prediction of small for gestational age neonates. International Journal of Gynecology and Obstetrics, 1988, 26, 81-87.	1.0	24
213	Steroidogenic acute regulatory protein (StAR) in the ovaries of healthy women and those with polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 2001, 185, 1381-1387.	0.7	24
214	Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA), a candidate gene for polycystic ovary syndrome. Human Reproduction, 2008, 23, 1214-1219.	0.4	24
215	Relations between Endogenous Androgens and Estrogens in Postmenopausal Women with Suspected Ischemic Heart Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4268-4275.	1.8	24
216	The Effect of 17Â-Estradiol on Adrenocortical Sensitivity, Responsiveness, and Steroidogenesis in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 519-524.	1.8	24

#	Article	IF	Citations
217	Dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome. Fertility and Sterility, 1999, 71, 436-438.	0.5	23
218	Metabolic and cardiovascular genes in polycystic ovary syndrome: A candidate-wide association study (CWAS). Steroids, 2012, 77, 317-322.	0.8	23
219	Adipocyte Insulin Resistance in PCOS: Relationship With GLUT-4 Expression and Whole-Body Glucose Disposal and Î²-Cell Function. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2408-e2420.	1.8	23
220	Steroidogenic Regulatory FactorFOSIs Underexpressed in Polycystic Ovary Syndrome (PCOS) Adipose Tissue and Genetically Associated with PCOS Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1750-E1757.	1.8	22
221	Acute myometritis and chorioamnionitis during cesarean section of asymptomatic women. American Journal of Obstetrics and Gynecology, 1988, 159, 1137-1139.	0.7	21
222	Magnetic resonance imaging of the adrenal gland in women with late-onset adrenal hyperplasia. Fertility and Sterility, 1991, 56, 142-144.	0.5	21
223	Abnormalities of 21-Hydroxylase Gene Ratio and Adrenal Steroidogenesis in Hyperandrogenic Women with an Exaggerated 17-Hydroxyprogesterone Response to Acute Adrenal Stimulation*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 1327-1331.	1.8	21
224	Prevalence of hyperandrogenemia among nonhirsute oligo-ovulatory women. Fertility and Sterility, 1997, 67, 569-572.	0.5	21
225	11Î²-hydroxyandrostenedione and Î´5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylaseâ€“deficient nonclassic adrenal hyperplasia. Fertility and Sterility, 1999, 72, 996-1000.	0.5	21
226	A variant of the glucocorticoid receptor gene is not associated with adrenal androgen excess in women with polycystic ovary syndrome. Fertility and Sterility, 2000, 74, 1237-1240.	0.5	21
227	Facial and abdominal hair growth in hirsutism: A computerized evaluation. Journal of the American Academy of Dermatology, 2001, 45, 846-850.	0.6	21
228	FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome. Human Reproduction, 2008, 23, 2842-2849.	0.4	21
229	The Associations Between Residents' Behavior and the Thomas-Kilmann Conflict MODE Instrument. Journal of Graduate Medical Education, 2010, 2, 118-125.	0.6	21
230	Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: report of the 4th special scientific meeting of the Androgen Excess and PCOS Society. Fertility and Sterility, 2010, 94, 690-693.	0.5	21
231	Racial and ethnic differences in the metabolic response of polycystic ovary syndrome. Clinical Endocrinology, 2020, 93, 163-172.	1.2	21
232	Prevalence of 21-hydroxylaseâ€“deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico. Fertility and Sterility, 2000, 74, 59-62.	0.5	20
233	Ovarian hormones and adrenal androgens during a woman's life span. Journal of the American Academy of Dermatology, 2001, 45, S105-S115.	0.6	20
234	How prevalent is metabolic syndrome in women with polycystic ovary syndrome?. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 132-133.	2.9	20

#	Article	IF	Citations
235	Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome. Fertility and Sterility, 2007, 87, 1473-1476.	0.5	20
236	A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 494173.	1.6	20
237	Minimal difference in phenotype between adolescents and young adults with polycystic ovary syndrome. Fertility and Sterility, 2019, 111, 389-396.	0.5	19
238	The 21-hydroxylase-deficient adrenal hyperplasias: More than ACTH oversecretion. Journal of the Society for Gynecologic Investigation, 1996, 3, 297-302.	1.9	19
239	Adrenal Androgens and Reproductive Aging in Females. Seminars in Reproductive Medicine, 1991, 9, 249-260.	0.5	18
240	Prevalence of 3Î²-hydroxysteroid dehydrogenaseâ€“deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess. American Journal of Obstetrics and Gynecology, 1999, 181, 596-600.	0.7	18
241	Environmental Pollutant Benzo[a]pyrene Induces Recurrent Pregnancy Loss through Promoting Apoptosis and Suppressing Migration of Extravillous Trophoblast. BioMed Research International, 2020, 2020, 1-10.	0.9	18
242	Does the risk of diabetes and heart disease in women with polycystic ovary syndrome lessen with age?. Fertility and Sterility, 2017, 108, 959-960.	0.5	18
243	No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease. Fertility and Sterility, 1991, 56, 1179-1182.	0.5	17
244	The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response. Fertility and Sterility, 1994, 61, 570-572.	0.5	17
245	Adrenal androgen production in response to adrenocorticotropin infusions in men. Endocrine Research, 1996, 22, 717-722.	0.6	17
246	Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism. Fertility and Sterility, 2021, 115, 1557-1568.	0.5	17
247	Regulation of extragonadal insulin-like growth factor-binding protein-3 by testosterone in oophorectomized women.. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1747-1751.	1.8	16
248	Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome. Human Reproduction, 1997, 12, 1138-1141.	0.4	16
249	Family size in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 85, 1837-1839.	0.5	16
250	11 beta-hydroxylase deficiency in hyperandrogenism. Fertility and Sterility, 1991, 55, 733-41.	0.5	16
251	Non-classic adrenal hyperplasia in hyperandrogenism: A reappraisal. Journal of Endocrinological Investigation, 1998, 21, 707-720.	1.8	15
252	Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome. Fertility and Sterility, 2002, 77, 1125-1127.	0.5	15

#	Article	IF	Citations
253	Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters. American Journal of Obstetrics and Gynecology, 2007, 196, 398.e1-398.e6.	0.7	15
254	Animal models for PCOS â€" not the real thing. Nature Reviews Endocrinology, 2017, 13, 382-384.	4.3	15
255	Screening for Androgen Excess in Women: Accuracy of Self-Reported Excess Body Hair Growth and Menstrual Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3688-e3695.	1.8	15
256	Family history as a risk factor for the polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism, 2000, 13 Suppl 5, 1303-6.	0.4	15
257	Operative endoscopy: the pressing need for a structured training and credentialing process. Fertility and Sterility, 1992, 58, 1100-1102.	0.5	14
258	Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). Clinical Chemistry and Laboratory Medicine, 2017, 55, 1789-1797.	1.4	14
259	Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. Journal of Women's Health, 2018, 27, 892-902.	1.5	14
260	Polycystic Ovary Syndrome Is a Family Affair. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1579-1581.	1.8	13
261	Effect of insulin and testosterone on androgen production and transcription of SULT2A1 in the NCI-h295r adrenocortical cell line. Fertility and Sterility, 2009, 92, 793-797.	0.5	13
262	Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome. Human Reproduction, 2017, 32, 185-192.	0.4	13
263	Pseudogene / functional gene ratio in late-onset 21-hydroxylase-deficient adrenal hyperplasia. American Journal of Obstetrics and Gynecology, 1990, 162, 633-638.	0.7	12
264	Harnessing Expression Data to Identify Novel Candidate Genes in Polycystic Ovary Syndrome. PLoS ONE, 2011, 6, e20120.	1.1	12
265	Genetic basis of eugonadal and hypogonadal female reproductive disorders. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 44, 3-14.	1.4	12
266	Adipocyte expression of glucose transporter 1 and 4 in PCOS: Relationship to insulinâ€mediated and nonâ€"insulinâ€mediated wholeâ€body glucose uptake. Clinical Endocrinology, 2019, 90, 542-552.	1.2	12
267	Regulation of extragonadal insulin-like growth factor-binding protein-3 by testosterone in oophorectomized women. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1747-1751.	1.8	12
268	Natural history of polycystic ovary syndrome: A systematic review of cardiometabolic outcomes from longitudinal cohort studies. Clinical Endocrinology, 2022, 96, 475-498.	1.2	12
269	Adrenal progestogen and androgen production in 21-hydroxylase-deficient nonclassic adrenal hyperplasia is partially independent of adrenocorticotropic hormone stimulation. Fertility and Sterility, 2002, 77, 750-753.	0.5	11
270	Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome. Fertility and Sterility, 2013, 99, 599-604.	0.5	11

#	Article	IF	Citations
271	Association study of androgen signaling pathway genes in polycystic ovary syndrome. Fertility and Sterility, 2016, 105, 467-473.e4.	0.5	11
272	Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome. Human Reproduction, 2022, 37, 553-564.	0.4	11
273	Diagnosing the diagnosis: why we must standardize the defining features of polycystic ovary syndrome. Annals of Clinical Biochemistry, 2008, 45, 3-5.	0.8	10
274	Basal metabolic rate in women with <scp>PCOS</scp> compared to eumenorrheic controls. Clinical Endocrinology, 2015, 83, 384-388.	1.2	10
275	Small leucine-rich proteoglycans (SLRPs) in the endometrium of polycystic ovary syndrome women: a pilot study. Journal of Ovarian Research, 2017, 10, 54.	1.3	10
276	Disparities in cardio metabolic risk between Black and White women with polycystic ovary syndrome: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 2021, 224, 428-444.e8.	0.7	10
277	Use of an oxidized, regenerated cellulose absorbable adhesion barrier at laparoscopy. Journal of reproductive medicine, The, 1991, 36, 479-82.	0.2	10
278	âˆ†5-Androstene-3Î²,17Î²-diol in healthy eumenorrheic women: relationship to body mass and hormonal profile*â€. Fertility and Sterility, 1994, 62, 321-326.	0.5	9
279	Early Adrenarche in Normal Prepubertal Girls: A Prospective Longitudinal Study. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 1231-7.	0.4	9
280	A twenty-first century research agenda for polycystic ovary syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 331-336.	2.2	9
281	Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 255-260.e2.	0.5	9
282	Comprehensive assessment of expression of insulin signaling pathway components in subcutaneous adipose tissue of women with and without polycystic ovary syndrome. Journal of Clinical and Translational Endocrinology, 2015, 2, 99-104.	1.0	9
283	The predictive value of total testosterone alone for clinical hyperandrogenism in polycystic ovary syndrome. Reproductive BioMedicine Online, 2020, 41, 734-742.	1.1	9
284	Training, Certification, and Credentialing in Gynecologic Operative Endoscopy. Clinical Obstetrics and Gynecology, 1995, 38, 313-318.	0.6	8
285	Androgen Response to Hypothalamic-Pituitary-Adrenal Stimulation with Naloxone in Women with Myotonic Muscular Dystrophy. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3219-3224.	1.8	8
286	Role of reproductive surgeons and the Society of Reproductive Surgeons1 1The opinions and commentary expressed in Editorâ€™s Corner articles are solely those of the author. Publication does not imply endorsement by the Editor or American Society for Reproductive Medicine.. Fertility and Sterility, 2002, 78, 916-917.	0.5	8
287	Alterations in plasma non-esterified fatty acid (NEFA) kinetics and relationship with insulin resistance in polycystic ovary syndrome. Human Reproduction, 2019, 34, 335-344.	0.4	8
288	Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndromeâ€"Based on liquid chromatography with tandem mass spectrometry measurements. Journal of Clinical Laboratory Analysis, 2019, 33, e22699.	0.9	8

#	Article	IF	Citations
289	Comprehensive evaluation of disparities in cardiometabolic and reproductive risk between Hispanic and White women with polycystic ovary syndrome in the United States: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 2022, 226, 187-204.e15.	0.7	8
290	Identifying and Developing Leadership Competencies in Health Research Organizations: A Pilot Study. The Journal of Health Administration Education, 2012, 29, 135-154.	0.5	8
291	Where are we in understanding the natural history of polycystic ovary syndrome? A systematic review of longitudinal cohort studies. Human Reproduction, 2022, 37, 1255-1273.	0.4	8
292	Dexamethasone Receptor Levels in Palatal and Lung Fibroblasts of Adult A/J and C57BL/6J Mice: Relationship to Glucocorticoid-Induced Cleft Palate. Cleft Palate-Craniofacial Journal, 1990, 27, 388-392.	0.5	7
293	Dexamethasone Receptor Levels in Palatal and Lung Fibroblasts of Adult A/J and C57BL/6J Mice: Relationship to Glucocorticoid-Induced Cleft Palate. The Cleft Palate Journal, 1990, 27, 388-392.	0.6	7
294	Impact of Architectural Disruption on Adrenocortical SteroidogenesisIn Vitro¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1017-1021.	1.8	7
295	We should avoid the indiscriminate use of insulin sensitizers in women with polycystic ovary syndrome. Fertility and Sterility, 2003, 80, 264-265.	0.5	7
296	The effectiveness of the interview for predicting the presence of polycystic ovary syndrome. Gynecological Endocrinology, 2003, 17, 449-454.	0.7	7
297	Evaluating Professionalism, Practice-Based Learning and Improvement, and Systems-Based Practice: Utilization of a Compliance Form and Correlation with Conflict Styles. Journal of Graduate Medical Education, 2010, 2, 423-429.	0.6	7
298	Reproductive hormone exposure timing and ischemic heart disease: Complicated answers to a simple question. Maturitas, 2010, 65, 297-298.	1.0	7
299	The Need to Reassess the Diagnosis of Polycystic Ovary Syndrome (PCOS): A Review of Diagnostic Recommendations from the International Evidence-Based Guideline for the Assessment and Management of PCOS. Seminars in Reproductive Medicine, 2021, 39, 071-077.	0.5	7
300	PCOS Phenotype in Unselected Populations Study (P-PUP): Protocol for a Systematic Review and Defining PCOS Diagnostic Features with Pooled Individual Participant Data. Diagnostics, 2021, 11, 1953.	1.3	7
301	21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia. , 1995, 5, 297-303.		6
302	Authorsâ€™ Response: Troglitazone Use in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5090-5091.	1.8	6
303	Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1. Reproductive Sciences, 2017, 24, 1005-1013.	1.1	6
304	Why we need epidemiologic studies of polycystic ovary syndrome in Africa. International Journal of Gynecology and Obstetrics, 2018, 143, 251-254.	1.0	6
305	Advantages and Disadvantages of Operative Endoscopy. , 1992, , 1-6.		6
306	No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease. Fertility and Sterility, 1991, 56, 1179-82.	0.5	6

#	Article	IF	Citations
307	Effect of obesity on the response to acute adrenocorticotropin stimulation in eumenorrheic women. Fertility and Sterility, 1991, 56, 427-33.	0.5	6
308	Differential diagnosis of clinically evident hyperandrogenism: experience with over 1000 consecutive patients.. Fertility and Sterility, 2001, 76, S111.	0.5	5
309	Prevalence of insulin resistance in Polycystic Ovary Syndrome (PCOS) patients using the Homeostatic Measurement Assessment (HOMA-IR). Fertility and Sterility, 2003, 80, 274-275.	0.5	5
310	Fifteenâ€year trend in the use of male reproductive surgery: analysis of the healthcare cost and utilization project data. BJU International, 2011, 107, 1118-1123.	1.3	5
311	What Is the Value and Role of Academic Medicine in the Life of Its University?. Academic Medicine, 2014, 89, 208-211.	0.8	5
312	Androgen-Insensitivity Syndrome: Long-Term Results of Surgical Vaginal Creation. Journal of Gynecologic Surgery, 1990, 6, 23-26.	0.0	4
313	Reproducibility of the adrenal androgen response to adrenocorticotropic hormone stimulation. Fertility and Sterility, 2006, 86, 484-486.	0.5	4
314	Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction, 2008, 23, 1474-1474.	0.4	4
315	Association study of AMP-activated protein kinase subunit genes in polycystic ovary syndrome. European Journal of Endocrinology, 2009, 161, 405-409.	1.9	4
316	Fifteen-year trend in the use of reproductive surgery in women in the United States. Fertility and Sterility, 2009, 92, 727-735.	0.5	4
317	Pregnancy-related economic burden ofÂpolycystic ovary syndrome (PCOS). Fertility and Sterility, 2019, 112, e43.	0.5	4
318	How polycystic ovary syndrome came into its own. F&S Science, 2021, 2, 2-10.	0.5	4
319	Impact of Architectural Disruption on Adrenocortical Steroidogenesis In Vitro. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1017-1021.	1.8	4
320	Profile of Daughters and Sisters of Women with Polycystic Ovary Syndrome: The Role of Probandâ€™s Glucose Tolerance. Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	4
321	The Degree of Menstrual Disturbance Is Associated With the Severity of Insulin Resistance in PCOS. Frontiers in Endocrinology, 0, 13, .	1.5	4
322	Late onset adrenal hyperplasia: mutation at codon 282 of the functional 21-hydroxylase gene is not ubiquitous**Presented in part at the 36th Annual Meeting of the Society for Gynecological Investigation, San Diego, California, March 15 to 18, 1989.. Fertility and Sterility, 1990, 54, 819-823.	0.5	3
323	The 21-Hydroxylase-Deficient Adrenal Hyperplasias: More Than ACTH Oversecretion. Journal of the Society for Gynecologic Investigation, 1996, 3, 297-302.	1.9	3
324	Should employer-sponsored health insurance benefits be made public?. Fertility and Sterility, 2002, 77, 216-217.	0.5	3

#	Article	IF	Citations
325	Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS) using age-specific DHEAS levels adjusted for body mass and ethnicity. Fertility and Sterility, 2003, 80, 46.	0.5	3
326	Are patients with idiopathic hirsutism (IH) insulin resistant?: Comparing women with IH to body mass index-matched patients with polycystic ovary syndrome (PCOS) and controls. Fertility and Sterility, 2004, 82, S301-S302.	0.5	3
327	O-26. Fertility and Sterility, 2006, 86, S12.	0.5	3
328	Overview of Long-Term Morbidity and Economic Cost of the Polycystic Ovary Syndrome. , 2006, , 353-362.		3
329	The 21-hydroxylase-deficient adrenal hyperplasias: more than ACTH oversecretion. Journal of the Society for Gynecologic Investigation, 1996, 3, 297-302.	1.9	3
330	O-078 Genotype and phenotype in women with 21-hydroxylase (21-OH) deficient non-classic adrenal hyperplasia (NCAH). Fertility and Sterility, 1997, 68, S39-S40.	0.5	2
331	P-075 Idiopathic hirsutism (IH): An uncommon cause of hirsutism in Alabama. Fertility and Sterility, 1997, 68, S128.	0.5	2
332	Adrenal Androgen Excess in the Polycystic Ovary Syndrome. , 2000, 10, 245-254.		2
333	A Faculty and Resident Development Program to Improve Learning and Teaching Skills. Journal of Graduate Medical Education, 2009, 1, 127-131.	0.6	2
334	Reply of the Authors: Criteria for the polycystic ovary syndrome. Fertility and Sterility, 2009, 92, e15.	0.5	2
335	Sexual function and polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and Sterility, 2016, 106, e261.	0.5	2
336	Health System Creation and Integration at a Health Sciences University. Journal of Healthcare Management, 2017, 62, 386-402.	0.4	2
337	Letter to the Editor Re: Casarini and Brigante, 2014, from Azziz R., et al. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L22-L23.	1.8	2
338	Authors' Response: Troglitazone Use in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5090a-5091.	1.8	2
339	The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response. Fertility and Sterility, 1994, 61, 570-2.	0.5	2
340	The different phenotypes of the polycystic ovary syndrome (PCOS).. Fertility and Sterility, 2001, 76, S208-S209.	0.5	1
341	Change in the diagnosis of patients with idiopathic hirsutism (IH) to Polycystic Ovary Syndrome (PCOS) due to the use of the 2003 Rotterdam criteria. Fertility and Sterility, 2004, 82, S298.	0.5	1
342	Reply: How many of the items in the polycystic ovary syndrome can be validated statistically?. Fertility and Sterility, 2006, 85, 530.	0.5	1

#	Article	IF	Citations
343	P-448. Fertility and Sterility, 2006, 86, S302.	0.5	1
344	Effect of sex steroids and insulin on dehydroepiandrosterone sulfate production by hepatoma G2 cells. Fertility and Sterility, 2009, 91, 2551-2556.	0.5	1
345	Anti-mullerian Hormone Receptor Type II Gene Polymorphisms Similar Among Women With the Polycystic Ovary Syndrome (PCOS) and Controls. Fertility and Sterility, 2009, 91, S6-S7.	0.5	1
346	Triglyceride to high-density lipoprotein cholesterol ratio as a predictor of insulin resistance in women with polycystic ovary syndrome (PCOS). Fertility and Sterility, 2011, 96, S129.	0.5	1
347	Abnormal Expression of Genes Involved in Inflammation, Lipid Metabolism, and Wnt Signaling in the Adipose Tissue of Polycystic Ovary Syndrome. Obstetrical and Gynecological Survey, 2012, 67, 707-709.	0.2	1
348	Women with polycystic ovary syndrome (PCOS) have lower basal metabolic rates compared to eumenorrheic controls. Fertility and Sterility, 2013, 100, S38-S39.	0.5	1
349	Sexual function in polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and Sterility, 2016, 106, e256.	0.5	1
350	Letter to the Editor: â€œType B Insulin Resistance Masquerading as Ovarian Hyperthecosisâ€• Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3865-3866.	1.8	1
351	Defining what is normal: theÂkey to the diagnosis of polycystic ovary syndrome (and any other) Tj ETQq1 1 0.784314 rgBT /Overlock	0.5	1
352	Adiposity in polycystic ovary syndrome: excess versus dysfunction. Fertility and Sterility, 2021, 116, 87-88.	0.5	1
353	Systemic chronic subclinical inflammation, adipose tissue dysfunction, and polycystic ovary syndrome: three major forces intertwined. Fertility and Sterility, 2021, 116, 1147-1148.	0.5	1
354	Clinical Features of the Polycystic Ovary Syndrome. , 2006, , 155-167.		1
355	Clinical and Hormonal Evaluation of Androgen Excess. , 2006, , 365-375.		1
356	Evaluation for Insulin Resistance and Comorbidities Related to Insulin Resistance in Polycystic Ovary Syndrome. , 2007, , 1-13.		1
357	Endocrinology of the Ovary. , 2005, , 391-403.		1
358	Editor's Formulation The Late-Onset Adrenal Hyperplasias: An Example of Molecular Biology Applied to the Study of Androgen Excess Disorders. Seminars in Reproductive Medicine, 1993, 11, 359-360.	0.5	0
359	Adrenocortical Dysfunction in Androgen Excess. Seminars in Reproductive Medicine, 1993, 11, 353-358.	0.5	0
360	Editor's Formulation Towards a Working Classification of Androgen Excess Disorders. Seminars in Reproductive Medicine, 1994, 12, 51-52.	0.5	0

#	Article	IF	Citations
361	On the â€œFirst International Symposium on the Developmental Aspects of Androgen Excessâ€¦The reviews in this issue are based on presentations made at the First International Symposium on the Developmental Aspects of Androgen Excess Disorders, 14â€“15 June 1997, Minneapolis, MN, USA.1. Trends in Endocrinology and Metabolism, 1998, 9, 45-46.	3.1	0
362	Why canâ€™t a man be more like a mouse?: Reply of the authors. Fertility and Sterility, 2001, 76, 856.	0.5	0
363	Adrenocortical dysfunction in polycystic ovary syndrome. , 2001, , 288-315.		0
364	Adrenal androgens in the polycystic ovary syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 469-474.	0.6	0
365	Obituary for John Benjamin Younger, Sr., M.D.. Fertility and Sterility, 2003, 80, 225-226.	0.5	0
366	Increased total and phosphorylated glycogen synthase kinase-3 (GSK-3) in the adipocytes of patients with the polycystic ovary syndrome (PCOS). Fertility and Sterility, 2004, 82, S90.	0.5	0
367	Reproducibility of adrenal androgen levels and their response to the adrenocorticotropic hormone (ACTH) stimulation test. Fertility and Sterility, 2004, 82, S301.	0.5	0
368	Family size in the Polycystic Ovary Syndrome (PCOS). Fertility and Sterility, 2004, 82, S307.	0.5	0
369	A Comparison of Insulin Action Between Women With 21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia (NCAH) and Polycystic Ovary Syndrome (PCOS). Fertility and Sterility, 2005, 84, S422.	0.5	0
370	P-870. Fertility and Sterility, 2006, 86, S457.	0.5	0
371	P-868. Fertility and Sterility, 2006, 86, S456-S457.	0.5	0
372	P-869. Fertility and Sterility, 2006, 86, S457.	0.5	0
373	O-197. Fertility and Sterility, 2006, 86, S84.	0.5	0
374	Heritability of Dehydroepiandrosterone Sulfate in Women With Polycystic Ovary Syndrome and Their Sisters. Obstetrical and Gynecological Survey, 2007, 62, 245-247.	0.2	0
375	Co-culture of adipocytes and resident macrophages affects monocyte chemoattractant protein-1 secretion in polycystic ovary syndrome. Fertility and Sterility, 2007, 88, S77-S78.	0.5	0
376	Metformin Use in Polycystic Ovary Syndrome: Metabolic Benefits and Diabetes Prevention. American Journal of Medicine, 2008, 121, e9.	0.6	0
377	Reply of the Authors: Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertility and Sterility, 2009, 91, e3-e3.	0.5	0
378	Relationship of ovarian morphology to degree of menstrual cycle dysfunction and insulin resistance in polycystic ovary syndrome (PCOS). Fertility and Sterility, 2010, 94, S69.	0.5	0

#	Article	IF	Citations
379	Body fat distribution and lean body mass (by CT scan) as a determinant of insulin resistence by FSIVGTT in polycystic ovary syndrome. Fertility and Sterility, 2010, 94, S70.	0.5	0
380	Use of fasting blood glucose levels to detect the presence of glucose intolerance in polycystic ovary syndrome (PCOS). Fertility and Sterility, 2010, 94, S71.	0.5	0
381	Variants in genes involved in androgen signaling as genetic determinants of polycystic ovary syndrome (PCOS). Fertility and Sterility, 2010, 94, S193.	0.5	0
382	The phenotype of polycystic ovary syndrome (PCOS) in Hispanic vs. non-Hispanic White women. Fertility and Sterility, 2010, 94, S193-S194.	0.5	0
383	Value of 1-hour versus 2-hour insulin levels during the oral glucose tolerance test (OGTT) for identifying the degree of hyperinsulinemia (HI) in PCOS women. Fertility and Sterility, 2010, 94, S195.	0.5	0
384	The severity of menstrual dysfunction serves as a predictor of insulin resistance in the polycystic ovary syndrome (PCOS). Fertility and Sterility, 2010, 94, S198.	0.5	0
385	DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results From the National Institutes of Healthâ€"National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Obstetrical and Gynecological Survey, 2011, 66, 143-144.	0.2	0
386	Polycystic ovary syndrome, microbiomics and why you should be a little selfish with your time. Expert Review of Endocrinology and Metabolism, 2013, 8, 329-331.	1.2	0
387	Replication of Genetic Variants for Polycystic Ovary Syndrome (PCOS) In a European Cohort. Fertility and Sterility, 2014, 101, e28.	0.5	0
388	Presidential and Academic Health Center Leadership within the Modern University. , 2015, , 13-21.		0
389	Metabolic features of adult and adolescent first-degree relatives of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and Sterility, 2017, 108, e248-e249.	0.5	0
390	Is hirsutism a marker of metabolic dysfunction?. Fertility and Sterility, 2019, 112, e389.	0.5	0
391	Screening for androgen excess in women: accuracy of self-reported excess body hair growth and menstrual dysfunction. Fertility and Sterility, 2019, 112, e45-e46.	0.5	0
392	Is antimÃ¼llerian hormone an early marker or an in utero effector of incipient polycystic ovary syndrome?. Fertility and Sterility, 2019, 111, 264-265.	0.5	0
393	Letter to the Editor: â€œDistribution of Body Hair in Young Australian Women and Associations with Serum Androgen Concentrationsâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3034-e3035.	1.8	0
394	Financial fluency: demystifying accounting and business planning for the reproductive medicine specialist. Fertility and Sterility, 2021, 115, 7-16.	0.5	0
395	Black Women Have a Worse Cardio-Metabolic Risk Profile Compared to White Women with Polycystic Ovary Syndrome in the United States: A Systematic Review and Meta-Analysis. Journal of the Endocrine Society, 2021, 5, A283-A284.	0.1	0
396	423 GENETIC VARIATION IN 5Î±-REDUCTASE INFLUENCES DEVELOPMENT OF POLYCYSTIC OVARY SYNDROME AND SEVERITY OF HIRSUTISM.. Journal of Investigative Medicine, 2006, 54, S152.3-S152.	0.7	0

#	Article	IF	Citations
397	Steroidogenic Regulatory Factor C-FOS Is Underexpressed in Polycystic Ovary Syndrome (PCOS) Adipose Tissue and Genetically Associated with PCOS Susceptibility. , 2010, , P1-344-P1-344.		0
398	Replication of Association of Insulin Receptor Gene Polymorphisms with Polycystic Ovary Syndrome (PCOS). , 2010, , P1-339-P1-339.		0
399	Development of Comprehensive Care Centers for Management of Patients with Congenital Adrenal Hyperplasia.. , 2010, , P3-723-P3-723.		0
400	The Impact of Proband Glucose Tolerance Status on Body Mass Index (BMI) and Adiposity in Adolescent Girls at High Risk for Polycystic Ovary Syndrome (PCOS). , 2010, , P1-341-P1-341.		0
401	Integration of Risk and Protective Alleles Predicts Susceptibility to Polycystic Ovary Syndrome. , 2010, , P1-340-P1-340.		0
402	Adrenocortical Dysfunction in the Polycystic Ovary Syndrome. , 1996, , 102-116.		0
403	Training, Certification, and Credentialing in Gynecologic Operative Endoscopy. , 1997, , 10-15.		0
404	Pathogenesis of Hyperandrogenism in Polycystic Ovary Syndrome. , 2008, , 281-294.		0
405	Pcos And Mendelian Randomization: Too Soon?. Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	0
406	New name, school still addressing physician shortages in Georgia. Journal of the Medical Association of Georgia, 2011, 100, 21, 37.	0.1	0